During the corresponding time, Medpace Holdings Inc recorded a revenue increase by 17.24 % year on year, sequentially revenue grew by 0.1 %. While revenue at the Medpace Holdings Inc 's corporate clients
Medpace Holdings Inc's Comment on Sales, Marketing and Customers
The company operates in the Phase I-IV contract research organization (CRO) market, conducting clinical trials across major therapeutic areas, including Oncology, Metabolic, Cardiology, Antiviral and Anti-infective (AVAI), and Central Nervous System (CNS). It serves small and mid-sized biopharmaceutical companies, providing clinical development services from Phase I to Phase IV. These services include medical department strategic direction, clinical trial management utilizing the ClinTrak system, data-driven feasibility analysis, global study start-up activities, patient recruitment and retention strategies, clinical monitoring by clinical research associates (CRAs), and risk-based monitoring to ensure compliance and data quality.
CINCINNATI Medpace Holdings, Inc. (Nasdaq: MEDP) has officially announced its plans to report the financial results for the fourth quarter and the entire fiscal year 2024 on February 10, 2025, after the market closes. This key announcement is poised to be a significant event for investors, analysts, and stakeholders, as it will provide detailed insights into the company’s financial health and operational performance over the past year.As a leading global contract research organization (CRO), Medpace specializes in providing comprehensive clinical development services to the biotechnology and pharmaceutical industries. With a focus on delivering high-quality data and results, Medpace has established itsel...
In a surprising turn of events, Medpace Holdings, Inc. (NASDAQ: MEDP) has seen its shares tumble following a disappointing bookings report for the third quarter of 2024. Investors were left reeling as Hagens Berman, a well-known legal firm, urged those who felt the impact of the company s financial missteps to come forward and submit their losses. This request signals that the firm believes there may be grounds for an investigation into the circumstances surrounding this unexpected shortfall.Despite a relatively strong performance in the second quarter of 2024 where the company achieved a return on assets (ROA) of 21.55%, significantly above its historically average ROA of 12.31% the recent bookings miss has...
Medpace Holdings Inc’s Comment on Sales, Marketing and Customers
The company operates in the Phase I-IV contract research organization (CRO) market, conducting clinical trials across major therapeutic areas, including Oncology, Metabolic, Cardiology, Antiviral and Anti-infective (AVAI), and Central Nervous System (CNS). It serves small and mid-sized biopharmaceutical companies, providing clinical development services from Phase I to Phase IV. These services include medical department strategic direction, clinical trial management utilizing the ClinTrak system, data-driven feasibility analysis, global study start-up activities, patient recruitment and retention strategies, clinical monitoring by clinical research associates (CRAs), and risk-based monitoring to ensure compliance and data quality.
Sources:
Medpace Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Medpace Holdings Inc’s corporate clients.
For your research, we’ve provided 9 tables on Medpace Holdings Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
199.9 %